0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Management of Patients With Sickle Cell Disease—Reply

Barbara P. Yawn, MD, MSc, MSPH1; George Buchanan, MD2; Kathryn Hassell, MD3
[+] Author Affiliations
1Department of Research and Education, Olmsted Medical Center, Rochester, Minnesota
2University of Texas Southwestern Medical Center, Dallas
3University of Colorado, Denver
JAMA. 2015;313(1):91-92. doi:10.1001/jama.2014.15909.
Text Size: A A A
Published online

Extract

In Reply Dr Pollack is concerned about the lack of evidence for deferasirox therapy in people with SCD and iron overload, as well as potential adverse effects and high costs. He refers to recent advances in the understanding of hepatic pathophysiology in handling iron and comments that this may apply to people with thalassemia, correctly pointing out that it is not clear if those data also apply to patients with SCD.1

Topics

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

January 6, 2015
Simeon Pollack, MD
1Department of Medicine, Albert Einstein College of Medicine, Bronx, New York
JAMA. 2015;313(1):90-91. doi:10.1001/jama.2014.15895.
January 6, 2015
Elizabeth S. Klings, MD; Gregory J. Kato, MD; Mark T. Gladwin, MD
1Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts
2Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania
3Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
JAMA. 2015;313(1):91. doi:10.1001/jama.2014.15898.
September 10, 2014
Barbara P. Yawn, MD, MSc, MSPH; George R. Buchanan, MD; Araba N. Afenyi-Annan, MD, MPH; Samir K. Ballas, MD; Kathryn L. Hassell, MD; Andra H. James, MD, MPH; Lanetta Jordan, MD, MPH, MSPH; Sophie M. Lanzkron, MD, MHS; Richard Lottenberg, MD; William J. Savage, MD, PhD; Paula J. Tanabe, PhD, RN; Russell E. Ware, MD, PhD; M. Hassan Murad, MD, MPH; Jonathan C. Goldsmith, MD; Eduardo Ortiz, MD, MPH; Robinson Fulwood, PhD, MSPH; Ann Horton, MS; Joylene John-Sowah, MD, MPH
1Olmsted Medical Center, Rochester, Minnesota
2University of Texas Southwestern Medical Center, Dallas
3University of North Carolina, Chapel Hill
4Thomas Jefferson University, Cardeza Foundation, Philadelphia, Pennsylvania
5University of Colorado, Denver
6University of Virginia, Charlottesville
7Foundation for Sickle Cell Disease Research, University of Miami, Miller School of Medicine, Miami, Florida
8Johns Hopkins School of Medicine, Baltimore, Maryland
9University of Florida, Gainesville
10Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
11Duke University, Schools of Nursing and Medicine, Durham, North Carolina
12Cincinnati Children’s Hospital Medical Center, Cincinatti, Ohio
13Mayo Clinic College of Medicine, Rochester, Minnesota
14National Heart, Lung, and Blood Institute, Bethesda, Maryland16Dr Goldsmith is now with the Rare Diseases Program, Office of New Drugs, US Food and Drug Administration, Bethesda, Maryland.
14National Heart, Lung, and Blood Institute, Bethesda, Maryland17Dr Ortiz is now a private senior consultant in Bethesda, Maryland.
14National Heart, Lung, and Blood Institute, Bethesda, Maryland18Dr Fulwood is now retired.
15American Institutes for Research, Silver Spring, Maryland
14National Heart, Lung, and Blood Institute, Bethesda, Maryland
JAMA. 2014;312(10):1033-1048. doi:10.1001/jama.2014.10517.
CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

664 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Jobs
brightcove.createExperiences();